MUC5AC antibody

Catalog No. ABIN3023895

The Mouse Monoclonal anti-MUC5AC antibody has been validated for IF, FACS and IHC (fro). It is suitable to detect MUC5AC in samples from Human, Mouse, Monkey, Cat and Cow.

Quick Overview for MUC5AC antibody (ABIN3023895)

Target: MUC5AC (Mucin 5AC, Oligomeric Mucus/gel-Forming (MUC5AC))

Reactivity: Human, Mouse, Monkey, Cat, Cow

Host: Mouse

Clonality: Monoclonal

Conjugate: This MUC5AC antibody is un-conjugated

Application: Immunofluorescence (IF), Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro))

Clone: 2-11M1

Product Details anti-MUC5AC Antibody

Characteristics: This mAb recognizes the peptide core of gastric mucin M1 (recently identified as Mucin 5AC). Its epitope is located in the N-terminal cysteine rich part of the peptide core of MUC5AC, which is heavily glycosylated. Its epitope is destroyed by beta-mercaptoethanol but not by periodate treatment. mAb 2-11M1 reacts with the protein backbone exclusively, it only reacts with fully deglycosylated MUC5AC. Therefore, the material under test should also be fully deglycosylated. This can be achieved with standard periodate oxidation method. The success of the deglycosylation can be checked with routine PAS (Periodic Acid Shiff) staining. After deglycosylation, the preparation should no longer be stainable with PAS reagent. Only then 2-11M1 will react should MUC5AC be present. This mucin is present in primary ovarian mucinous cancer but usually absent in colorectal adenocarcinoma, thus showing an expression pattern opposite to MUC2. Together with a panel of antibodies, Anti-MUC5AC may be useful for differential identification of primary mucinous ovarian tumors from colon adenocarcinoma metastatic to the ovary. MUC5AC antibodies may also be useful for identification of intestinal metaplasia as well as in the identification of pancreatic carcinoma and pre-cancerous changes vs. normal pancreas.

Purification: Protein G affinity chromatography

Immunogen: An M1 mucin preparation from the fluid of an ovarian mucinous cyst belonging to an O Le(a-b) patient was used as the immunogen for the MUC5AC antibody.

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal dilution of the MUC5AC antibody should be determined by the researcher.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 1-2 μg/mL,Immunohistochemistry (Frozen): 0.5-1 μg/mL for 30 min at RT

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: Store the MUC5AC antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Target Details for MUC5AC

Target: MUC5AC (Mucin 5AC, Oligomeric Mucus/gel-Forming (MUC5AC))

Alternative Name: MUC5AC

Background: This mAb recognizes the peptide core of gastric mucin M1 (recently identified as Mucin 5AC). Its epitope is located in the N-terminal cysteine rich part of the peptide core of MUC5AC, which is heavily glycosylated. Its epitope is destroyed by beta-mercaptoethanol but not by periodate treatment. mAb 2-11M1 reacts with the protein backbone exclusively, it only reacts with fully deglycosylated MUC5AC. Therefore, the material under test should also be fully deglycosylated. This can be achieved with standard periodate oxidation method. The success of the deglycosylation can be checked with routine PAS (Periodic Acid Shiff) staining. After deglycosylation, the preparation should no longer be stainable with PAS reagent. Only then 2-11M1 will react should MUC5AC be present. This mucin is present in primary ovarian mucinous cancer but usually absent in colorectal adenocarcinoma, thus showing an expression pattern opposite to MUC2. Together with a panel of antibodies, Anti-MUC5AC may be useful for differential identification of primary mucinous ovarian tumors from colon adenocarcinoma metastatic to the ovary. MUC5AC antibodies may also be useful for identification of intestinal metaplasia as well as in the identification of pancreatic carcinoma and pre-cancerous changes vs. normal pancreas.